CENTOGENE Reports First Half 2023 Financial Results : compar

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial PerformanceFirst half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth...

Related Keywords

Peter Bauer , Bayern , Germany , Saudi Arabia , United States , Cambridge , Cambridgeshire , United Kingdom , Berlin , America , Melissa Hall , Lennart Streibel , Miguel Coego , Kim Stratton , Mary Sheahan , Exchange Commission , Share Base Payments , Saudi Arabia Public Investment Fund , Management Board Of The Company , Rare Disease Panel , Contract Research Organizations Cros , Linkedin , Drug Administration , Hereditary Oncology Panel , Twist Alliance , Public Investment Fund , Supervisory Board Of The Company , Corporate Communications , Gulf Cooperation Council , Strong Revenues , Steady Growth , Both Diagnostics , Pharma Segments Drive Sustainable Financial , Joint Venture , Chief Executive Officer , Whole Exome Sequencing , Whole Genome Sequencing , Chief Financial Officer , General Meeting , Management Board , Peer Schatz , Supervisory Board , Premier Research , Contract Research Organizations , Denali Therapeutics , European Journal , Human Genetics , Copy Number Variations , Next Generation Sequencing , Disease Panel , Oncology Panel , Novaseqx Plus Sequencer , Share Based Payments , Oxford Loan Facility , Insight Reports , Markets ,